Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Pharmacovigilance Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The pharmacovigilance market size has experienced rapid growth in recent years. It is anticipated to expand from $9.64 billion in 2025 to $10.86 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 12.7%. The expansion observed in the historic period can be attributed to increasing adverse drug reaction reporting, expansion of global pharmaceutical approvals, rising clinical trial volumes, establishment of international drug safety regulations, and growth in chronic disease drug usage.
The pharmacovigilance market is anticipated to undergo significant expansion in the coming years, with its size projected to reach $17.41 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 12.5%. This growth during the forecast period is attributed to several factors, including the increasing utilization of real-world data, a rise in approvals for biologics and biosimilars, the escalating complexity of combination therapies, the expansion of pharmacovigilance activities into emerging markets, and a heightened focus on patient safety outcomes. Prominent trends expected in this period encompass the broadening of post-marketing surveillance efforts, a growing reliance on real-world evidence in safety monitoring, more rigorous regulatory oversight and compliance demands, an increase in the outsourcing of pharmacovigilance services, and the integration of diverse safety data platforms.
Get A Free Sample Report With In-Depth Market Insights:
Pharmacovigilance Market Demand Drivers: What’s Powering Industry Growth?
Elevated levels of research and development undertakings are projected to fuel the expansion of the pharmacovigilance market. Through strategic investment in R&D, pharmaceutical firms are able to create novel and cutting-edge medications featuring enhanced safety profiles. Thorough preclinical and clinical evaluations conducted throughout the drug development cycle facilitate the prompt detection of possible safety issues, thereby enabling the deployment of suitable risk mitigation tactics. Furthermore, R&D initiatives contribute significantly to the progression of technologies utilized for adverse event surveillance, data analytics, and signal identification, thus aiding the swift discovery of adverse drug reactions during the post-marketing period. As an illustration, in 2023, data from the Office for National Statistics, a UK-based government agency, showed that the UK government’s net expenditure on research and development (R&D) climbed to £17.4 billion in 2023, an increase from £16.1 billion in 2022, representing an 8.2% rise. Consequently, the heightened engagement in research and development activities has effectively bolstered the expansion of the pharmacovigilance market.
Pharmacovigilance Market Segment Outlook: Which Categories Are Growing Fastest?
The pharmacovigilance market covered in this report is segmented –
1) By Type: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining
2) By Service Provider: In-House, Contract Outsourcing
3) By Process Flow: Case Data Management, Signal Detection, Risk Management System
4) By Clinical Trial Phases: Preclinical, Phase I, Phase II, Phase III, Phase IV
5) By End User: Hospitals, Pharmaceutical Companies, Other End Users
Subsegments:
1) By Spontaneous Reporting: Individual Case Safety Reports (ICSRs), Voluntary Reporting Systems, Case Reports From Healthcare Professionals
2) By Intensified ADR Reporting: Active Surveillance Programs, Enhanced Monitoring In Clinical Trials, Risk Minimization Strategies
3) By Targeted Spontaneous Reporting: Reporting For Specific Drug Classes, Condition-Specific Reporting, Focused Surveillance Programs
4) By Cohort Event Monitoring: Prospective Cohort Studies, Retrospective Cohort Studies, Longitudinal Studies
5) By EHR Mining: Data Extraction From Electronic Health Records, Signal Detection Through EHR Analysis, Integration Of EHR Data With Pharmacovigilance Systems
Pharmacovigilance Market Innovation Trends: What Developments Are Reshaping The Industry?
Leading companies within the pharmacovigilance market are increasingly concentrating on artificial intelligence (AI) to enhance their operational efficiency. AI has the potential to boost the effectiveness and precision of pharmacovigilance activities, ultimately resulting in improved patient outcomes. By leveraging AI, pharmaceutical firms can streamline their operations, optimize data management, and accelerate drug discovery, concurrently lowering costs and increasing safety. For example, in August 2024, the Government of India introduced the Adverse Drug Reaction Monitoring System (ADRMS) software, launched by the Minister of Health & Family Welfare and Minister of Chemicals and Fertilizers. This pharmacovigilance software assists in the collection and analysis of adverse events associated with medicines and medical devices, thereby simplifying the reporting process for both consumers and healthcare professionals. This initiative considerably strengthens India’s pharmacovigilance infrastructure by ensuring a more extensive capture of safety data and elevating drug safety monitoring. The ADRMS endeavors to improve the efficiency of drug safety oversight and adherence to standards, thereby helping to establish India as a prominent player in the global pharmaceutical industry.
Pharmacovigilance Market Leading Companies And Competitive Benchmarking
Major companies operating in the pharmacovigilance market are IQVIA, Cognizant, ICON Plc, Accenture plc, PAREXEL International Corporation, United BioSource LLC, ArisGlobal, Quanticate, Wipro Limited, Linical Americas, Novotech CRO, EXTEDO, Arriello, PrimeVigilance, Axios International, C3i Solutions, Secure AI Labs, OmniSol dot Tech, Prevnos Inc., Lifescient Inc, QuintilesIMS, Labcorp Drug Development, Pharmaceutical Product Development Inc., PRA Health Sciences, Synowledge LLC, RAPAhub, illuminate health, Invenio Medical, ClinChoice Inc., Novasyte, Fortrea Holdings Inc., Syneos Health Clinical, Telerx Marketing Inc.
View The Full Pharmacovigilance Market Report:
Pharmacovigilance Market Regional Analysis And Top Geography
North America was the largest region in the pharmacovigilance market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast region. The regions covered in the pharmacovigilance market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Leave a Reply